JP2697725B2 - Malignant tumor treatment kit - Google Patents
Malignant tumor treatment kitInfo
- Publication number
- JP2697725B2 JP2697725B2 JP8184245A JP18424596A JP2697725B2 JP 2697725 B2 JP2697725 B2 JP 2697725B2 JP 8184245 A JP8184245 A JP 8184245A JP 18424596 A JP18424596 A JP 18424596A JP 2697725 B2 JP2697725 B2 JP 2697725B2
- Authority
- JP
- Japan
- Prior art keywords
- leu
- ala
- gln
- ser
- pro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
【発明の詳細な説明】
【0001】
【発明の属する技術分野】本発明はヒト顆粒球コロニー
刺激因子(以下ヒトG−CSFと略記する)を有効成分
とする製剤と抗悪性腫瘍血清との組み合わせからなる悪
性腫瘍治療用キットに関する。
【0002】
【従来の技術】本発明は造血因子(hemopoiet
ic growth factor)の1つであるヒト
G−CSFを用いて、悪性腫瘍の治療に役立てようとす
るものであって、直接これに関連する報告類の見当たら
ない新規な悪性腫瘍治療用キットを提供しようとするも
のである。ヒトG−CSFはin Vitroの実験系
において顆粒球の前駆細胞に働き顆粒球への分化増進を
促す機能を有している造血因子である〔例えばMetc
alf.et.al:Exp.Hematol.1,1
85,(1973)等参照〕。ところがこのヒトG−C
SFは今迄入手するのが極めて困難であったため、医薬
としての有用性又は有効性についての検討が充分進展せ
ず、本発明が目的とするガンの治療への可能性について
も未検討のままに置かれていた。
【0003】
【発明が解決しようとする課題】この様な状況を打開す
べく、本出願人は研究を重ねた結果、遺伝子工学等によ
るヒトG−CSFの製造方法の開発に成功し、純粋均質
でしかも大量のヒトG−CSFが入手できるようになっ
た(特願昭59−153273号、特願昭60−269
455号、特願昭60−269456号、特願昭60−
270838号、特願昭60−270839号等参
照)。この成果をふまえて、殺悪性腫瘍作用を有するヒ
ト成熟顆粒球に対するヒトG−CSFの影響等を研究
し、そこで得られた知見にもとづいて副作用の少ない優
れた悪性腫瘍治療用キットを開発しようとするのが本発
明の目的である。
【0004】
【課題を解決するための手段】本発明者らは上記目的を
達成するため、鋭意研究を重ねた結果、悪性腫瘍細胞例
えばヒト悪性黒色腫細胞(HMV)において、
ヒトG−CSF存在下で前孵置した顆粒球は、非存在
下で前孵置した顆粒球に比べて約2〜4倍の殺HMV効
果が認められた。
殺HMV効果は正常ウサギ血清の存在下で影響されな
いが、抗HMV血清の存在下ではその濃度に依存して最
高10〜30倍に増強した。
ヒトG−CSFとの前孵置による顆粒球の殺HMV効
果の増強の程度は、ヒトG−CSFの濃度と明らかな相
関がある。
という事実を確認し、この結果からヒトG−CSFはヒ
ト成熟顆粒球(特に好中球)の殺悪性腫瘍作用を抗悪性
腫瘍血清存在下で著しく亢進させることを見出し本発明
に到達した。即ち、本発明は抗ヒト悪性腫瘍血清とヒト
顆粒球コロニー刺激因子を有効性分とする製剤の組み合
わせからなる悪性腫瘍治療用キットを提供するものであ
る。
【0005】以下本発明を詳細に説明する。本発明のG
−CSFを有効性分とする製剤に含まれるヒトG−CS
Fは純度の高いヒトG−CSFであればその由来が制限
されるものではなく、例えば人の生体試料から抽出、分
離、精製したもの、ヒトG−CSF産生細胞を培養し、
その培養上清から単離したもの、細胞融合法を用いてヒ
トG−CSF産生ハイブリドーマを形成しこれから取得
したもの、遺伝子組換えによって、大腸菌、動物細胞等
の宿主を形質転換して得た形質転換体から産生せしめ単
離精製したもの、又はそれを化学修飾したもの等のいず
れも使用することができる。
【0006】しかし、それらの中でも純度よく均質大量
に入手できる本出願人が製造した次の(1)及び(2)
で示すヒトG−CSFが特に好ましいものである。
(1)次の理化学的性質を有するヒトG−CSF。
分子量:ドデシル硫酸ナトリウム−ポリアクリルアミ
ドゲル電気泳動法による測定で約19,000±1,0
00。
等電点:pI=5.5±0.1,pI=5.8±0.
1,pI=6.1±0.1の三つの等電点のうち少なく
とも1つを有する。
紫外部吸収:280nmに極大吸収を有し、250n
mに極小値をもつ。
N末端から21残基目迄のアミノ酸配列が次の如くで
ある。
H2 N−Thr−Pro−Leu−Gly−Pro−A
la−Ser−Ser−Leu−Pro−Gln−Se
r−Phe−Leu−Leu−Lys−Cys−Leu
−Glu−Gln−Val−
【0007】(2)配列番号1、2、3又は4のアミノ
酸配列またはその一部で表わされるヒト顆粒球コロニー
刺激因子活性を有するポリペプチド又はこれと糖鎖部を
有する糖蛋白質を含有するヒトG−CSF。上記のヒト
G−CSFは例えば後述する参考例に示す方法によって
製造することができる。即ち、上記(1)のヒトG−C
SFは参考例1によって、又(2)のヒトG−CSFは
参考例2に示す方法により得ることができる。なおこれ
らの方法の詳細な製造条件については、本出願人が先に
出願した特願昭59−153273号,特願昭60−2
69455号,特願昭60−269456号,特願昭6
0−270838号,特願昭60−270839号の各
明細書を参照されたい。
【0008】又、その他の方法としてG−CSF産生細
胞と自己増殖能を有する悪性腫瘍細胞とを細胞融合して
得られるハイブリドーマをマイトジェンの存在または非
存在下で培養することによって得ることもできる。これ
等の方法で得たヒトG−CSFは全て本発明に含まれ
る。得られたヒトG−CSF含有液は必要により公知の
手段でさらに精製、濃縮した後凍結保存とするかまたは
凍結乾燥、真空乾燥などの手段により水分を除去して保
存することができる。また所望によりヒトG−CSFを
適当な緩衝液に溶解した後、ミリポアフィルター等で無
菌濾過して注射剤とすることもできる。ヒトG−CSF
を有効性分とする製剤はヒトまたは動物医薬用に適した
医薬製剤としての形態をとるために必要な製薬担体や賦
形剤を、さらには安定化剤、吸着防止剤を含むことがで
きる。
【0009】次に本発明の悪性腫瘍治療用キットについ
て説明する。後述する実験例(薬理効果)から明らかな
通り、ヒトG−CSFは抗悪性腫瘍血清の存在下で著し
く顆粒球の殺悪性腫瘍作用を増大する。これは、該抗血
清が顆粒球の腫瘍細胞認識力を高め、それへのとりつき
を容易にする結果、顆粒球(特に好中球)の殺悪性腫瘍
作用の効果が一段と向上をするためと推定される。この
作用効果をガン治療に活用すべく開発したのが抗悪性腫
瘍血清とヒトG−CSFを有効成分とする製剤の組み合
わせからなる本発明の悪性腫瘍治療用キットである。
【0010】ヒトG−CSFを有効成分とする製剤に含
まれるヒトG−CSFの投与量、投与回数は対象の疾患
患者の病状を配慮して決めることができるが、通常成人
一人当たり0.1〜500μg、好ましくは0.5〜2
00μgのヒトG−CSFを含有する製剤を1週間に1
〜7回投与することができる。しかし本発明はヒトG−
CSFの含有量によって限定されるものではない。本キ
ットで用いられる抗悪性腫瘍血清は公知の方法で調製さ
れたものでよく、その投与量は通常成人一人当たり0.
1〜5ccである。又、該抗悪性腫瘍血清の投与方法と
しては、本発明の抗悪性腫瘍剤投与により顆粒球が増加
し、それがピークとなる約1時間前頃に静脈注射等の注
射によって投与するのがよい。
【0011】
【発明の実施の形態】以下本発明を参考例(ヒトG−C
SFの製造例)実験例(薬理効果)、実施例(製剤例)
をあげて説明するが、本発明はこれらに限定されるもの
ではない。なお、抗腫瘍血清不存在下の結果を参考とし
て併記した。
【0012】参考例1 (G−CSF産生細胞の培養に
よるヒトG−CSFの製造例)
特願昭59−153273号の実施例1に示す方法で樹
立したヒト口腔底癌細胞由来のG−CSF産生細胞株C
HU−1(C.N.C.M受託番号「I−315」)ま
たは同様の方法で樹立した細胞株CHU−2(C.N.
C.M受託番号「I−483」)をウシ胎児血清を含有
するRPMI 1640培養液に浮遊した後、ローラー
ボトルにいれて回転培養を行った。細胞がローラーボト
ル内壁に密に増殖したところで培養液を血清不含RPM
I 1640にかえ、4日間培養後上清を回収。次いで
血清含有RPMI 1640を加えて3日間培養した
後、培養液を血清不含RPMI 1640に液替し、4
日間培養後上清を回収する。以下これを繰返し培養上清
を回収した。得られた血清不含培養上清を限界ろ過で約
1000倍に濃縮し精製、次いで検定を行った。精製及
び検定は前記特願昭59−153273号明細書の実施
例と同じ方法で行った。
【0013】参考例2 (遺伝子組換えによるヒトG−
CSFの製造例)
本出願人によって微工研に寄託されているエシエリヒア
・コリ(E.Coli)χ1776R−2株(FERM
BP−955)から切り出してきたヒトG−CSF遺
伝子を有するcDNA断片をベクターpdKCRに組み
込みpHGV2プラスミドとした後これをSalIで処
理し、次いでDNAポリメラーゼ−Klenow断片を
反応させる。このDNAにEcoRIリンカーを付加
し、再びEcoRIで部分消化した後、アガロースゲル
電気泳動にて約2.7Kbのフラグメントを回収する。
【0014】一方、pAdD26SVpAプラスミド
(Kaufman,R.G.& Sharp,P,A.
(1982)Mol.Cell.Biol,2巻130
4〜1319)をEcoRIで処理し、BAP処理し、
脱リン酸する。次でフェノール処理後電気泳動でpAd
D26SVpAのEcoRI断片を回収した。上記の
2.7kb断片とpAdD26SVpA断片をアニール
し、E.coli DHI株に塩化ルビジウム法により
形質転換してpHGV2−dhfrプラスミドを得た。
【0015】つぎにCHO細胞(dhfr−株、コロン
ビア大学Dr.L.Chasinより入手)を9cm径
のプレート(Nunc社製)中10%仔牛血清を含むα
最小必須培地(α−MEM,アデノシン、デオキシアデ
ノシン、チミジン添加)で培養増殖し、これをリン酸−
カルシウム法(Wigler等、Cell14巻725
頁(1978))によって形質転換した。即ち、前記の
pHGV2−dhfrプラスミド1μgにキヤリア−D
NA(子牛胸線DNA)を適量加えて、TE溶液375
μlに溶解し1M CaCl2 125μlを加える。3
〜5分氷上で冷やし500μlの2×HBS(50mM
Hepes、280mM NaCl、1.5mMリン酸
緩衝液)を加え再び氷冷後、上記のCHO細胞培養液1
mlと混合し、プレートに移し、CO2 インキュベータ
ー中で9時間培養する。
【0016】以下洗浄、20%グリセロール含有TBS
(Tris−buffered saline)添加、
再び洗浄した後非選択培地(前出α−MEM培地、ヌク
レオシド添加)を添加して2日間インキュベートし、選
択培地で1:10に細胞を分割した。次いで2日毎に選
択培地(ヌクレオシド無添加)にて培地交換を行いなが
ら培養を続行し生じた集塊(foci)を選別して新し
いプレートに移した。新しいプレートでは0.02μM
メトトレキセート(MTX)存在下で増殖し再び0.1
μM MTX存在下で増殖させてクローニングを行っ
た。更にクローニングを続けた結果10mg/l以上の
ヒトG−CSFの生産を確認した。なお、精製、検定は
特願昭60−269456号明細書の実施例2及び15
の記載の方法によって行った。
【0017】実験例1
〔顆粒球の殺黒色腫細胞(HMV)効果と添加抗HMV
血清及びヒトG−CSF濃度変動の影響〕dextra
n沈降法、Ficoll−Hypaque(1.07
7)重層遠心法、低張ショック赤血球除去法を用いて、
健常者末梢血顆粒球を分離した(純度及び生細胞率90
%以上)。分離された細胞に種々の濃度のヒトG−CS
Fを添加し培養液中で37℃、1時間インキュベートし
た後、洗浄し、ヒト成熟顆粒球の調製をした。
【0018】次に一定数のヒト悪性黒色腫細胞株(HM
V)をマイクロプレート中で培養し、生細胞が充分にウ
エル底に付着したところで表1に示す各濃度のウサギ正
常血清又は抗HMV血清と上記の調製済みの一定数の成
熟顆粒球を添加し、37℃,24時間培養した。その後
各ウエルを培養液で洗浄し、付着して生存している細胞
の数を染色後算定した。結果を表1に示す。
【0019】表1から明らかな通り、ヒトG−CSFを
添加し調製した顆粒球は無添加の場合に比べ約2〜4倍
の殺HMV効果が認められ、且つ抗HMV血清を添加す
るとその傾向がいっそう顕著となる。又、ヒトG−CS
Fとのインキュベートによる顆粒球の殺HMV効果の増
強の程度にはヒトG−CSFの濃度と明らかな相関がみ
られる。これらの結果はヒトG−CSFがヒト成熟顆粒
球の殺HMV作用を著しく亢進することを明らかにして
いる。
【0020】
【表1】【0021】実験例2
〔顆粒球の殺黒色腫細胞効果と添加ヒトG−CSF及び
抗HMV血清濃度変動の影響〕一定数のHMVをマイク
ロプレート中で培養し、生細胞が充分にウエル底に付着
したところで表2に示す各濃度の抗HMV血清又は正常
血清を添加し、次で実験例1と同様にして調製した活性
化顆粒球又は非活性化顆粒球を加え、37℃,24時間
インキュベートした。その後各ウエルを培養液で洗浄し
付着生存している細胞の数を染色後算定した。結果を表
2に示す。
【0022】表2より明らかな通り、殺HMV効果は正
常血清の存在下では影響されないが、抗HMV血清の存
在下ではその濃度に依存して最高約30倍に増強される。
又、実験例1の結果と同様にヒトG−CSFで活性化さ
れた顆粒球はヒトG−CSFを用いた非活性の顆粒球に
比べ殺HMV効果が正常血清添加下でも2倍以上優れて
おり、この差は抗HMV血清存在下ではより顕著になる
ことがわかる。これらの結果はヒトG−CSFが抗HM
V血清存在下でヒト成熟顆粒球の殺HMV作用を顕著に
亢進せしめる働きがあることを示している。
【0023】
【表2】
【0024】実験例3
〔ヒトG−CSFの有無と顆粒球又はリンパ球の各種腫
瘍細胞に対する殺効果〕実験例1と同様にして健常者末
梢血顆粒球及びリンパ球を分離し、ヒトG−CSFを添
加後インキュベートし、活性化させた。コントロールと
してはヒトG−CSFを添加せずに同様にインキュベー
トしたものを用意した。一方、表3に示す各腫瘍細胞に
上記の活性化顆粒球又は非活性化顆粒球もしくはリンパ
球を加え、インキュベートし、各種腫瘍細胞のDNA合
成を[ 3H]サイミジンの取り込み率でみた。結果を表
3に示す。表3より明らかな通り、HMVだけでなく他
の腫瘍細胞に対してもヒトG−CSFは成熟顆粒球の殺
腫瘍細胞作用を亢進させることが認められる。一方リン
パ球には顆粒球のような効果は認められない。
【0025】
【表3】
【0026】上記の実験の結果をまとめると前述した通
り、
ヒトG−CSF存在下で前孵置した顆粒球は、非存在
下で孵置した顆粒球に比べて約2〜4倍の殺HMV効果
が認められた。
殺HMV効果は正常ウサギ血清の存在下で影響されな
いが、抗HMV血清の存在下ではその濃度に依存して最
高10〜30倍に増強した。
ヒトG−CSFとの前孵置による顆粒球の殺HMV効
果の増強の程度は、ヒトG−CSFの濃度と明らかな相
関があった。
上記の傾向はHMV以外の腫瘍細胞に対しても同様に
認められた。したがって、ヒトG−CSFはヒト成熟顆
粒球の殺腫瘍細胞作用を抗腫瘍血清存在下で著しく亢進
させることが確認された。
【0027】
【実施例】本発明は以下の実施例(製剤例)で得られた
ヒトG−CSFを含有する製剤と抗ヒト悪性腫瘍血清の
製剤を組み合わせてキットとするものであるが、本発明
はこれらの組み合わせに限定されるものではない。
【0028】実施例1(製剤例)
参考例1によって得られ且つ精製されたヒトG−CSF
を無菌処理した後−20℃で凍結された凍結物を用いて
注射剤とした。
【0029】実施例2(製剤例)
参考例2によって得られ且つ精製されたヒトG−CSF
を無菌操作で10mlバイアル瓶に5ml充填し、−2
0℃で凍結乾燥後ゴム栓にて施栓した凍結乾燥物を用い
て注射剤とした。
【0030】実施例3(製剤例)
HMV細胞をウサギに免疫して得られた抗HMV血清を
フィルター滅菌処理した後−20℃で凍結させた凍結物
を用いて注射剤とした。
【0031】
【発明の効果】本発明の悪性腫瘍治療用キットは人の体
にもともと存在しているヒト成熟顆粒球の抗腫瘍作用を
純化されたヒトG−CSFによって増強し、且つ抗腫瘍
細胞血清を併存せしめることによって、さらに一段と増
強させ、この作用にもとづいて悪性腫瘍を治療しようと
するものであり、副作用の少ないガン治療剤となる期待
が大きい。
【0032】
【配列表】
配列番号:1
配列の長さ:174
配列の形:アミノ酸
鎖の数:
トロポジー:直鎖状
配列の種類:ペプチド
配列
Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys 16
Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln 32
Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val 48
Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys 64
Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser 80
Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser 96
Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp 112
Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro 128
Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe 144
Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe 160
Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 174
【0033】配列番号:2
配列の長さ:175
配列の形:アミノ酸
鎖の数:
トロポジー:直鎖状
配列の種類:ペプチド
配列
Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu 16
Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu 32
Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 48
Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 64
Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 80
Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile 96
Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala 112
Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala 128
Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala 144
Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 160
Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 175
【0034】配列番号:3
配列の長さ:177
配列の形:アミノ酸
鎖の数:
トロポジー:直鎖状
配列の種類:ペプチド
配列
Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys 16
Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln 32
Glu Lys Leu Val Ser Glu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu 48
Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu 64
Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln 80
Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu 96
Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp 112
Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly 128
Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala 144
Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu 160
Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln 176
Pro 177
【0035】配列番号:4
配列の長さ:178
配列の形:アミノ酸
鎖の数:
トロポジー:直鎖状
配列の種類:ペプチド
配列
Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu 16
Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu 32
Gln Glu Lys Leu Val Ser Glu Cys Ala Thr Tyr Lys Leu Cys His Pro 48
Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro 64
Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser 80
Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu 96
Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu 112
Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu 128
Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe 144
Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His 160
Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala 176
Gln Pro 178Description: TECHNICAL FIELD [0001] The present invention relates to a combination of a preparation containing human granulocyte colony stimulating factor (hereinafter abbreviated as human G-CSF) as an active ingredient and an anti-malignant tumor serum. And malignant tumor treatment kits. [0002] The present invention relates to hematopoietic factors.
A novel kit for treating malignant tumors, which is intended to be useful for treating malignant tumors by using human G-CSF, which is one of the ic growth factors, and for which there are no reports directly related thereto. What you want to do. Human G-CSF is a hematopoietic factor having a function of acting on progenitor cells of granulocytes in an in vitro experimental system and promoting the promotion of differentiation into granulocytes [for example, Metec
alf. et. al: Exp. Hematol. 1,1
85, (1973) etc.]. However, this human GC
Since SF has been extremely difficult to obtain until now, studies on its usefulness or efficacy as a medicine have not been sufficiently advanced, and the possibility of the present invention for the treatment of cancer remains unexamined. Was placed in [0003] To overcome such a situation, the present applicant has made repeated studies and as a result, has succeeded in developing a method for producing human G-CSF by genetic engineering or the like, and has succeeded in developing a pure homogenous method. In addition, a large amount of human G-CSF has become available (Japanese Patent Application Nos. 59-153273 and 60-269).
No. 455, Japanese Patent Application No. 60-269456, Japanese Patent Application No. 60-269
No. 270,838, Japanese Patent Application No. 60-270839). Based on this result, we studied the effects of human G-CSF on human mature granulocytes having a malignant tumor-suppressing action, and developed an excellent kit for treating malignant tumors with few side effects based on the findings. It is the purpose of the present invention. Means for Solving the Problems The present inventors have conducted intensive studies in order to achieve the above-mentioned object, and as a result, the presence of human G-CSF in malignant tumor cells, for example, human malignant melanoma cells (HMV). The granulocytes pre-hatched below had about 2 to 4 times the HMV killing effect compared to the granulocytes pre-hatched in the absence. The HMcidal effect was not affected in the presence of normal rabbit serum, but in the presence of anti-HMV serum it was enhanced up to 10-30 fold depending on its concentration. The degree of enhancement of the granulocytic HMV killing effect by pre-incubation with human G-CSF has a clear correlation with the concentration of human G-CSF. From the results, the present inventors have found that human G-CSF markedly enhances the malignant killing effect of human mature granulocytes (particularly neutrophils) in the presence of anti-malignant tumor serum, and reached the present invention. That is, the present invention provides a kit for treating a malignant tumor, comprising a combination of an anti-human malignant tumor serum and a preparation containing human granulocyte colony stimulating factor as an active ingredient. Hereinafter, the present invention will be described in detail. G of the present invention
-Human G-CS contained in a preparation containing CSF as an active ingredient
The origin of F is not limited as long as it is high-purity human G-CSF. For example, extracted, separated and purified from a human biological sample, and cultured human G-CSF-producing cells,
A product isolated from the culture supernatant, a product obtained by forming a human G-CSF-producing hybridoma using a cell fusion method, and a product obtained by transforming a host such as Escherichia coli or an animal cell by genetic recombination. Any of those produced from the transformant, isolated and purified, or those chemically modified can be used. [0006] However, among them, the following (1) and (2) produced by the present applicant, which can be obtained in a large quantity with good purity and uniformity,
Are particularly preferred. (1) Human G-CSF having the following physicochemical properties. Molecular weight: about 19,000 ± 1,0 determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
00. Isoelectric point: pI = 5.5 ± 0.1, pI = 5.8 ± 0.
It has at least one of three isoelectric points of 1, pI = 6.1 ± 0.1. Ultraviolet absorption: maximum absorption at 280 nm, 250 n
m has a minimum value. The amino acid sequence from the N-terminal to the 21st residue is as follows. H 2 N-Thr-Pro-Leu-Gly-Pro-A
la-Ser-Ser-Leu-Pro-Gln-Se
r-Phe-Leu-Leu-Lys-Cys-Leu
-Glu-Gln-Val- (2) a polypeptide having the activity of human granulocyte colony-stimulating factor represented by the amino acid sequence of SEQ ID NO: 1, 2, 3 or 4, or a part thereof, A human G-CSF containing a glycoprotein. The above-mentioned human G-CSF can be produced, for example, by a method shown in Reference Examples described later. That is, the human GC of the above (1)
SF can be obtained according to Reference Example 1, and human G-CSF of (2) can be obtained by the method described in Reference Example 2. The detailed production conditions of these methods are described in Japanese Patent Application No. 59-153273 and Japanese Patent Application No. 60-2, filed earlier by the present applicant.
No. 69455, Japanese Patent Application No. 60-269456, Japanese Patent Application No. 6
See Japanese Patent Application Nos. 0-270838 and 60-270839. [0008] Alternatively, it can be obtained by culturing a hybridoma obtained by cell fusion of a G-CSF producing cell and a malignant tumor cell having self-proliferation ability in the presence or absence of mitogen. All human G-CSF obtained by these methods are included in the present invention. If necessary, the obtained human G-CSF-containing liquid can be further purified and concentrated by known means and then stored frozen, or can be stored by removing moisture by means such as freeze-drying or vacuum drying. If desired, human G-CSF can be dissolved in an appropriate buffer, and then sterile-filtered with a Millipore filter or the like to prepare an injection. Human G-CSF
Can contain a pharmaceutical carrier and excipients necessary for taking a form as a pharmaceutical preparation suitable for human or veterinary medicine, as well as a stabilizer and an anti-adsorption agent. Next, the kit for treating malignant tumors of the present invention will be described. As is clear from the experimental examples (pharmacological effects) described later, human G-CSF significantly increases the activity of granulocytes in killing tumors in the presence of anti-malignant tumor serum. This is presumed to be because the antiserum enhances the ability of granulocytes to recognize tumor cells and facilitates their attachment to the cells, and as a result, the effect of granulocytes (particularly neutrophils) on malignant tumors is further improved. Is done. A kit for treating a malignant tumor of the present invention, which comprises a combination of an anti-malignant tumor serum and a preparation containing human G-CSF as an active ingredient, has been developed in order to utilize this effect in treating cancer. [0010] The dose and frequency of administration of human G-CSF contained in a preparation containing human G-CSF as an active ingredient can be determined in consideration of the disease state of the target disease patient. ~ 500 μg, preferably 0.5-2
A formulation containing 00 μg of human G-CSF is administered once a week.
It can be administered up to 7 times. However, the present invention relates to human G-
It is not limited by the content of CSF. The anti-malignant tumor serum used in this kit may be prepared by a known method, and its dosage is usually 0.1 to 0.1 per adult.
1 to 5 cc. As an administration method of the anti-malignant tumor serum, it is preferable to administer the anti-malignant tumor agent of the present invention by injection such as intravenous injection about one hour before the administration of the anti-malignant tumor agent increases granulocytes and peaks. . DETAILED DESCRIPTION OF THE INVENTION The present invention is described below with reference to a reference example (human GC).
Production example of SF) Experimental example (pharmacological effect), Example (formulation example)
However, the present invention is not limited to these. The results in the absence of antitumor serum are also shown for reference. Reference Example 1 (Example of production of human G-CSF by culturing G-CSF-producing cells) G-CSF derived from human oral floor cancer cells established by the method shown in Example 1 of Japanese Patent Application No. 59-153273. Producing cell line C
HU-1 (CNCM accession number "I-315") or a cell line CHU-2 (CN.
C. M accession number "I-483") was suspended in RPMI 1640 culture solution containing fetal calf serum, and then placed in a roller bottle for spin-culture. When the cells have grown densely on the inner wall of the roller bottle, the culture solution is subjected to serum-free RPM.
After 1 day of culture, the supernatant was recovered in place of I 1640. Next, after adding serum-containing RPMI 1640 and culturing for 3 days, the culture solution was changed to serum-free RPMI 1640,
After culturing for one day, collect the supernatant. Hereinafter, this was repeated to collect the culture supernatant. The obtained serum-free culture supernatant was concentrated and purified about 1000-fold by ultrafiltration, and then assayed. Purification and assay were carried out in the same manner as in the examples of the specification of Japanese Patent Application No. 153273/1984. Reference Example 2 (Human G-
Example of Production of CSF) E. coli strain # 1776R-2 (FERM) deposited by the present applicant with the microfabrication laboratory.
A cDNA fragment having the human G-CSF gene cut out from BP-955) is incorporated into a vector pdKCR to form a pHGV2 plasmid, which is then treated with SalI, and then reacted with a DNA polymerase-Klenow fragment. After adding an EcoRI linker to the DNA and partially digesting it again with EcoRI, a fragment of about 2.7 Kb is recovered by agarose gel electrophoresis. On the other hand, the pAdD26SVpA plasmid (Kaufman, RG & Sharp, P, A .;
(1982) Mol. Cell. Biol, Vol. 130
4 to 1319) with EcoRI, BAP processing,
Dephosphorylate. Next, after phenol treatment, pAd by electrophoresis
The EcoRI fragment of D26SVpA was recovered. above
The 2.7 kb fragment and the pAdD26SVpA fragment were annealed, The E. coli DHI strain was transformed by the rubidium chloride method to obtain a pHGV2-dhfr plasmid. Next, CHO cells (dhfr - strain, obtained from Dr. L. Chasin, Columbia University) were placed in a 9 cm-diameter plate (manufactured by Nunc) containing α containing 10% calf serum.
Cultivated and grown in a minimum essential medium (α-MEM, adenosine, deoxyadenosine, thymidine added), and
Calcium method (Wigler et al., Cell 14, 725)
(1978). That is, Carrier-D was added to 1 μg of the above pHGV2-dhfr plasmid.
Add an appropriate amount of NA (calf chestline DNA) and add TE solution 375
Dissolve in μl and add 125 μl of 1M CaCl 2 . 3
Cool on ice for 〜5 minutes and 500 μl of 2 × HBS (50 mM
Hepes, 280 mM NaCl, 1.5 mM phosphate buffer) and ice-cooled again.
mix with the plate, transfer to a plate and incubate for 9 hours in a CO 2 incubator. Washing, TBS containing 20% glycerol
(Tris-buffered saline),
After washing again, a non-selective medium (α-MEM medium, with nucleosides) was added and incubated for 2 days, and the cells were split 1:10 in the selective medium. Subsequently, the culture was continued while exchanging the medium with a selection medium (no nucleoside added) every two days, and the resulting clumps (foci) were selected and transferred to a new plate. 0.02 μM for new plate
Grow in the presence of methotrexate (MTX) and regrow
Cloning was performed by growing in the presence of μM MTX. As a result of continuing cloning, production of human G-CSF of 10 mg / l or more was confirmed. The purification and assay were performed according to Examples 2 and 15 of Japanese Patent Application No. 60-269456.
Was performed according to the method described in the above section. Experimental Example 1 [Melanoma cell (HMV) effect of granulocytes and added anti-HMV
Effect of Fluctuations in Serum and Human G-CSF Concentration] dextra
n sedimentation method, Ficoll-Hypaque (1.07
7) Using a multilayer centrifugation method and a hypotonic shock red blood cell removal method,
Normal human peripheral blood granulocytes were separated (purity and viable cell ratio 90
%that's all). Various concentrations of human G-CS were added to the separated cells.
After adding F and incubating at 37 ° C. for 1 hour in the culture solution, washing was performed to prepare human mature granulocytes. Next, a certain number of human malignant melanoma cell lines (HM
V) was cultured in a microplate, and when the living cells had sufficiently adhered to the well bottom, rabbit normal serum or anti-HMV serum at each concentration shown in Table 1 and a certain number of the prepared mature granulocytes prepared above were added. And incubated at 37 ° C for 24 hours. Thereafter, each well was washed with a culture solution, and the number of adherent and surviving cells was calculated after staining. Table 1 shows the results. As is clear from Table 1, the granulocytes prepared by adding human G-CSF showed about 2 to 4 times the HMV killing effect as compared with the case where no G-CSF was added, and the tendency was observed when anti-HMV serum was added. Becomes more pronounced. Also, human G-CS
The degree of enhancement of the granulocytic HMV killing effect by incubation with F has a clear correlation with the concentration of human G-CSF. These results demonstrate that human G-CSF significantly enhances the HMV killing effect of mature human granulocytes. [Table 1] Experimental Example 2 [Melanoma Cell Effect of Granulocytes and Effect of Fluctuations in Serum Concentration of Added Human G-CSF and Anti-HMV] A certain number of HMVs were cultured in a microplate, and the viable cells were sufficiently placed on the well bottom. When adhered, anti-HMV serum or normal serum at each concentration shown in Table 2 was added, and then activated or non-activated granulocytes prepared as in Experimental Example 1 were added, and incubated at 37 ° C. for 24 hours. did. Thereafter, each well was washed with a culture solution, and the number of cells surviving adherence was calculated after staining. Table 2 shows the results. As is clear from Table 2, the HMV killing effect is not affected in the presence of normal serum, but is enhanced up to about 30-fold in the presence of anti-HMV serum depending on its concentration.
In addition, similarly to the result of Experimental Example 1, the granulocytes activated with human G-CSF are more than twice as effective in inactivating HMV even in the presence of normal serum as compared with inactive granulocytes using human G-CSF. It can be seen that this difference becomes more pronounced in the presence of anti-HMV serum. These results indicate that human G-CSF has anti-HM
This shows that the presence of V serum has a function to markedly enhance the HMV killing effect of human mature granulocytes. [Table 2] Experimental Example 3 [Presence / absence of human G-CSF and killing effect of granulocytes or lymphocytes on various tumor cells] Peripheral blood granulocytes and lymphocytes of healthy subjects were separated in the same manner as in Experimental Example 1, and human G-CSF was isolated. After addition of CSF, it was incubated and activated. As a control, one that was similarly incubated without adding human G-CSF was prepared. On the other hand, the above-mentioned activated granulocytes or non-activated granulocytes or lymphocytes were added to each tumor cell shown in Table 3, and incubated, and the DNA synthesis of various tumor cells was examined by the incorporation rate of [ 3 H] thymidine. Table 3 shows the results. As is evident from Table 3, it can be seen that human G-CSF enhances the tumoricidal cell effect of mature granulocytes not only on HMV but also on other tumor cells. On the other hand, lymphocytes do not have the same effect as granulocytes. [Table 3] To summarize the results of the above experiments, as described above, granulocytes pre-incubated in the presence of human G-CSF are about 2 to 4 times more HMV killed than granulocytes hatched in the absence of human G-CSF. The effect was recognized. The HMcidal effect was not affected in the presence of normal rabbit serum, but in the presence of anti-HMV serum it was enhanced up to 10-30 fold depending on its concentration. The degree of enhancement of the granulocytic HMV killing effect by pre-incubation with human G-CSF was clearly correlated with the concentration of human G-CSF. The above tendency was similarly observed for tumor cells other than HMV. Therefore, it was confirmed that human G-CSF markedly enhances the tumoricidal cell effect of human mature granulocytes in the presence of antitumor serum. The present invention relates to a kit comprising a combination of the preparation containing human G-CSF obtained in the following examples (preparation examples) and a preparation of anti-human malignant tumor serum. The invention is not limited to these combinations. Example 1 (Formulation Example) Human G-CSF obtained and purified according to Reference Example 1
Was aseptically treated and used as an injection using a frozen product frozen at -20 ° C. Example 2 (Formulation Example) Human G-CSF obtained and purified according to Reference Example 2
Is filled into a 10 ml vial by aseptic operation in an amount of 5 ml.
After freeze-drying at 0 ° C., the freeze-dried product sealed with a rubber stopper was used as an injection. Example 3 (Preparation Example) An anti-HMV serum obtained by immunizing rabbits with HMV cells was subjected to filter sterilization, and then frozen at -20 ° C to prepare an injection. The kit for treating malignant tumors of the present invention enhances the antitumor activity of human mature granulocytes originally present in the human body by purified human G-CSF, and provides antitumor cells. By coexisting serum, it is further enhanced, and it is intended to treat malignant tumors based on this effect, and is expected to be a therapeutic agent for cancer with few side effects. [Sequence List] SEQ ID NO: 1 Sequence length: 174 Sequence form: Number of amino acid chains: Tropoie: Type of linear sequence: Peptide sequence Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys 16 Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln 32 Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val 48 Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys 64 Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser 80 Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser 96 Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp 112 Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro 128 Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe 144 Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe 160 Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 174 [SEQ ID NO: 2] Sequence length: 175 Sequence form: Number of amino acid chains: Troposi: Type of linear sequence: Peptide sequence Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu 16 Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu 32 Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 48 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 64 Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 80 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile 96 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala 112 Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala 128 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala 144 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 175 [SEQ ID NO: 3] Sequence length: 177 Sequence form: Number of amino acid chains: Tropoie: Type of linear sequence: Peptide sequence Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys 16 Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln 32 Glu Lys Leu Val Ser Glu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu 48 Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu 64 Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln 80 Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu 96 Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp 112 Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly 128 Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala 144 Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu 160 Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln 176 Pro 177 SEQ ID NO: 4 Sequence length: 178 Sequence form: Number of amino acid chains: Topoposite: Type of linear sequence: Peptide sequence Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu 16 Lys Cys Leu Glu Gln Va l Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu 32 Gln Glu Lys Leu Val Ser Glu Cys Ala Thr Tyr Lys Leu Cys His Pro 48 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro 64 Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser 80 Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu 96 Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu 112 Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu 128 Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe 144 Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His 160 Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala 176 Gln Pro 178
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 //(C12P 21/02 C12R 1:19) ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 6 Identification code Agency reference number FI Technical indication location // (C12P 21/02 C12R 1:19)
Claims (1)
を有効成分とする製剤の組み合わせからなる悪性腫瘍治
療用キット。 2.悪性腫瘍が悪性黒色腫であることを特徴とする請求
項1記載の悪性腫瘍治療用キット。 3.ヒト顆粒球コロニー刺激因子が好中球コロニー刺激
因子であることを特徴とする請求項1記載の悪性腫瘍治
療用キット。 4.ヒト顆粒球コロニー刺激因子がヒト顆粒球コロニー
刺激因子産生細胞の培養上清から得られたものであるこ
とを特徴とする請求項1記載の悪性腫瘍治療用キット。 5.ヒト顆粒球コロニー刺激因子が次の理化学的性質を
有するものであることを特徴とする請求項1記載の悪性
腫瘍治療用キット。 「理化学的性質」 分子量:ドデシル硫酸ナトリウム−ポリアクリルアミ
ドゲル電気泳動法による測定で19,000±1,00
0。 等電点:pI=5.5±0.1,pI=5.8±0.
1,pI=6.1±0.1の三つの等電点のうち少なく
とも1つを有する。 紫外部吸収:280nmに極大吸収を有し、250n
mに極少値をもつ。 N末端から21残基目迄のアミノ酸配列が次の如くで
ある。 H2 N−Thr−Pro−Leu−Gly−Pro−A
la−Ser−Ser−Leu−Pro−Gln−Se
r−Phe−Leu−Leu−Lys−Cys−Leu
−Glu−Gln−Val− 6.ヒト顆粒球コロニー刺激因子がヒト顆粒球コロニー
刺激因子活性を有するポリペプチドをコードする遺伝子
を含む組換えベクターを含有する形質転換体から産生さ
れたヒト顆粒球コロニー刺激因子活性を有するポリペプ
チドまたは糖蛋白質であることを特徴とする請求項1記
載の悪性腫瘍治療用キット。 7.ヒト顆粒球コロニー刺激因子活性を有するポリペプ
チドが下記のアミノ酸配列またはその一部で表わされる
請求項1項記載の悪性腫瘍治療用キット。 (Met)n Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu (Val Ser Glu )m Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro (但しmは0又は1を表わし、nは0又は1を表わす) 8. ヒト顆粒球コロニー刺激因子活性を有する糖蛋白
質が下記のアミノ酸配列またはその一部で表わされるポ
リペプチドと糖鎖部とを有するものである請求項1項記
載の悪性腫瘍治療用キット。 Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu (Val Ser Glu) m Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro (ただし mは0または1を表わす)。(57) [Claims] A malignant tumor treatment kit comprising a combination of an anti-human malignant tumor serum and a preparation containing human granulocyte colony-stimulating factor as an active ingredient. 2. The malignant tumor treatment kit according to claim 1, wherein the malignant tumor is malignant melanoma. 3. The kit for treating a malignant tumor according to claim 1, wherein the human granulocyte colony stimulating factor is a neutrophil colony stimulating factor. 4. The kit for treating a malignant tumor according to claim 1, wherein the human granulocyte colony stimulating factor is obtained from a culture supernatant of a human granulocyte colony stimulating factor-producing cell. 5. The kit for treating a malignant tumor according to claim 1, wherein the human granulocyte colony stimulating factor has the following physicochemical properties. "Physicochemical properties" Molecular weight: 19,000 ± 1,000 as measured by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
0. Isoelectric point: pI = 5.5 ± 0.1, pI = 5.8 ± 0.
It has at least one of three isoelectric points of 1, pI = 6.1 ± 0.1. Ultraviolet absorption: maximum absorption at 280 nm, 250 n
m has a minimal value. The amino acid sequence from the N-terminal to the 21st residue is as follows. H 2 N-Thr-Pro-Leu-Gly-Pro-A
la-Ser-Ser-Leu-Pro-Gln-Se
r-Phe-Leu-Leu-Lys-Cys-Leu
-Glu-Gln-Val- 6. Polypeptide or sugar having human granulocyte colony stimulating factor activity produced from a transformant containing a recombinant vector containing a gene encoding a polypeptide having human granulocyte colony stimulating factor having human granulocyte colony stimulating factor activity The kit for treating a malignant tumor according to claim 1, which is a protein. 7. The kit for treating a malignant tumor according to claim 1, wherein the polypeptide having human granulocyte colony-stimulating factor activity is represented by the following amino acid sequence or a part thereof. (Met) n Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu (Val Ser Glu) m Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro (where m represents 0 or 1 and n represents 0 or 1) 7) The kit for treating a malignant tumor according to claim 1, wherein the glycoprotein having human granulocyte colony-stimulating factor activity has a polypeptide represented by the following amino acid sequence or a part thereof and a sugar chain portion. Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu (Val Ser Glu) m Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro (where m represents 0 or 1).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8184245A JP2697725B2 (en) | 1986-09-13 | 1996-06-26 | Malignant tumor treatment kit |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61-215035 | 1986-09-13 | ||
JP21503586 | 1986-09-13 | ||
JP8184245A JP2697725B2 (en) | 1986-09-13 | 1996-06-26 | Malignant tumor treatment kit |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP62226450A Division JP2589094B2 (en) | 1986-09-13 | 1987-09-11 | Antineoplastic agent |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08333274A JPH08333274A (en) | 1996-12-17 |
JP2697725B2 true JP2697725B2 (en) | 1998-01-14 |
Family
ID=26502389
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8184245A Expired - Lifetime JP2697725B2 (en) | 1986-09-13 | 1996-06-26 | Malignant tumor treatment kit |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2697725B2 (en) |
-
1996
- 1996-06-26 JP JP8184245A patent/JP2697725B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JPH08333274A (en) | 1996-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI234583B (en) | Hyperglycosylated analogs of human erythropoietin and pharmaceutical composition thereof, DNA sequences encoding said analogs, and host cells comprising said sequences | |
EP0494268B1 (en) | Method for inhibiting growth of stem cells | |
AU606056B2 (en) | Production of m-csf | |
JPS6230A (en) | Remedy for malignant tumorous anemia | |
KR950003492B1 (en) | Thrombus control agent | |
US5582822A (en) | Treatment of leukemia using interleukin 2 | |
US6447766B1 (en) | Method of mobilizing hematopoietic stem cells | |
US20050063948A1 (en) | Methods for targeting interleukin-12 to malignant endothelium | |
JP3030386B2 (en) | Anticancer agent | |
JP2697725B2 (en) | Malignant tumor treatment kit | |
WO1992012177A1 (en) | Novel megakaryocyte amplifier and production thereof | |
JP2589094B2 (en) | Antineoplastic agent | |
JP2019516363A (en) | Fusion protein containing CCL3 mutant and use thereof | |
JPH083058A (en) | New medicine for bone metabolic disease | |
EP0401379B1 (en) | STABILIZED COMPOSITION OF INTERLEUKIN-1$g(b) | |
CN111732631B (en) | Polypeptide and application thereof in preparation of medicines for treating and preventing tumors | |
EP0560998A1 (en) | Medicine for preventing and treating bleeding tendency | |
JP2838867B2 (en) | Stem cell proliferation promoter | |
US20030077818A1 (en) | Compositions and methods for targeting interleukin-12 to malignant endothelium | |
EP0308424A1 (en) | A novel protein, neuroleukin | |
EP0412105A1 (en) | Stem cell inhibitors | |
JPH0618780B2 (en) | Myeloid leukemia inhibitor | |
WO1999026645A1 (en) | Method of mobilizing hematopoietic stem cells | |
Edgington et al. | MOLECULAR CLONING OF HUMAN TISSUE FACTOR cDNA | |
JPS62292726A (en) | Analgesic and anti-inflammatory agent containing interleukin 1 as active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |